as required under Regulation 30 we are attaching the Outcome of Board Meeting held and also attached Annexure I as required by you. Kindly note the same. Director
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Colinz Laboratories' Board, at its meeting on 17th January 2026, approved the sale of its factory building, machinery, and land located at Sinnar, Nashik to M/s. Hilsun Foods and Drugs Private Limited for a total consideration of Rs. 4 crore, payable in tranches. The buyer is an unrelated third party and the transaction is at arm's length. Shareholders had already approved this sale via Postal Ballot on 17th November 2025 under Regulation 37A of SEBI LODR. The sale agreement is expected to be executed and completed on or before 31st March 2026. The Board also authorized Whole-time Director & CEO Mr. Narayan Kutty Menon to finalize and sign the sale agreement.
The company is divesting its manufacturing factory assets, which represents a significant restructuring step. Shareholders should monitor how the Rs. 4 crore proceeds will be redeployed, as the factory was a core operational asset for this pharma/lab company. The stock may see short-term volatility as investors assess the company's future business direction without its manufacturing base.